Your session is about to expire
← Back to Search
Radiation Therapy
SABR for Lung Cancer (SUPPRESS-NSCLC Trial)
Phase 2
Recruiting
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Oligoprogression while on ICI or TKI (any line)
Metastatic NSCLC enrolled in our CRCHUM Lung Cancer Registry and co-enrolled to the PERa registry
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
SUPPRESS-NSCLC Trial Summary
This trial is testing whether a new cancer treatment is better than the current standard of care.
Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer who have limited progression in up to 5 body sites while on current cancer drugs. They must be able to consent, have a performance status of 0-3, and not be pregnant or breastfeeding. Lesions must be smaller than 5 cm and not involve the GI tract.Check my eligibility
What is being tested?
The study compares standard care options versus adding stereotactic ablative radiotherapy (SABR) to existing systemic therapy for patients whose lung cancer has progressed but remains limited. Patients are randomly assigned to either continue/change their current treatment or receive SABR alongside it.See study design
What are the potential side effects?
Potential side effects from SABR may include skin reactions, fatigue, shortness of breath, chest pain, and inflammation around treated areas. The severity can vary based on individual health conditions and previous treatments.
SUPPRESS-NSCLC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer has spread in a limited way while on immunotherapy or targeted therapy.
Select...
I am registered in the CRCHUM Lung Cancer and PERa registries with metastatic NSCLC.
Select...
I am 18 years old or older.
Select...
I can care for myself but may not be able to do heavy physical work.
SUPPRESS-NSCLC Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
OS
PFS
Secondary outcome measures
Grade ≥ 3 toxicity
Local control
Quality of life 5-level EQ-5D (EQ-5D-5L)
+2 moreSide effects data
From 2007 Phase 4 trial • 552 Patients • NCT001108907%
Diarrhoea
7%
Vomiting
3%
Nausea
3%
Nasopharyngitis
3%
Muscle spasms
1%
Jaundice
1%
Fluid retention
1%
Shunt thrombosis
1%
Cognitive disorder
1%
Pancreatic carcinoma
1%
Angina pectoris
1%
Myocardial infarction
1%
Pericarditis
1%
Shunt occlusion
1%
Gastroenteritis
1%
Hernia
1%
Chest discomfort
1%
Arteriovenous fistula thrombosis
1%
Skin ulcer
1%
Hypovolaemia
1%
Hypertensive crisis
1%
Joint dislocation
1%
Joint injury
1%
Blood potassium increased
1%
Catheter placement
1%
Arteriovenous fistula occlusion
1%
Orthostatic hypotension
1%
Cardiac arrest
1%
Chest pain
1%
Pyrexia
1%
Cholecystitis
1%
Arthritis bacterial
1%
Bacterial sepsis
1%
Fall
1%
Back pain
1%
Pain in extremity
1%
Dyspnoea
1%
Nephrectomy
1%
Hypotension
1%
Peripheral ischaemia
1%
Atrial flutter
1%
Cardiac asthma
1%
Abdominal pain
1%
Sudden cardiac death
1%
Transplant rejection
1%
Perianal abscess
1%
Pneumonia
1%
Urinary tract infection
1%
Ankle fracture
1%
Arteriovenous fistula site complication
1%
Rib fracture
1%
Cerebral infarction
1%
Gastrointestinal haemorrhage
1%
Catheter related infection
1%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard Care
Cinacalcet
SUPPRESS-NSCLC Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental SABR armExperimental Treatment1 Intervention
Definitive SABR to oligoprogressive lesions + continue current systemic therapy
Group II: Standard of careActive Control1 Intervention
Switch to subsequent systemic therapy line, best supportive care or continue current systemic line
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
366 Previous Clinical Trials
129,569 Total Patients Enrolled
Houda Bahig, MD PhDStudy ChairCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
106 Total Patients Enrolled
Bertrand Routy, MD PhDStudy ChairCentre hospitalier de l'Université de Montréal (CHUM)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer has spread to my spine or digestive system.My cancer has spread to 1-5 spots outside the brain, affecting up to 3 organs, and is under 5cm.My cancer has spread in a limited way while on immunotherapy or targeted therapy.I had treatments like radiation or surgery for cancer spread before my current treatment.I am registered in the CRCHUM Lung Cancer and PERa registries with metastatic NSCLC.My cancer can be safely targeted with SABR according to my doctor.I have brain metastasis but it's being treated according to standard care.I am 18 years old or older.I can care for myself but may not be able to do heavy physical work.I have a tumor larger than 5 cm.
Research Study Groups:
This trial has the following groups:- Group 1: Standard of care
- Group 2: Experimental SABR arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the desired outcome of this investigation?
"This research study will assess the primary objective of Overall Survival (OS) over a five-year period. Secondary outcomes include Local Control, Quality of Life assessed using the EQ-5D-5L questionnaire and FACT-G tool, as well as CTCAE Patient Reported Outcomes measured with the PRO-CTCAE method."
Answered by AI
What is the aggregate number of participants enrolled in this experiment?
"Affirmative, the details on clinicaltrials.gov verify that this research is presently recruiting participants. This trial was first published on May 1st 2021 and last edited on April 24th 2022. 68 volunteers must be enrolled across one medical facility."
Answered by AI
Are new participants being admitted to this trial presently?
"Indeed, records on clinicaltrials.gov demonstrate that this trial is still recruiting participants and has been since January 5th 2021. With only 68 subjects required from a single location, the recruitment process should be brief."
Answered by AI
Is the conventional treatment protocol sanctioned by the FDA?
"Safety data for Standard of Care was assessed to be a 2 as it is only currently being studied in Phase 2 trials; there are indications that the treatment may be safe, but efficacy has yet to be established."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger